Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Diseases of the Thyroid

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    February 2024
  1. CHOI H, Cho SW, Kim HH, Yi KH, et al
    Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
    Cancer. 2024 Feb 20. doi: 10.1002/cncr.35256.
    PubMed     Abstract available


    May 2023

  2. Erratum to "Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma".
    Cancer. 2023 May 2. doi: 10.1002/cncr.34829.
    PubMed    


    April 2023
  3. YAN L, Li Y, Li XY, Xiao J, et al
    Clinical outcomes of ultrasound-guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: A retrospective study with more than 5 years of follow-up.
    Cancer. 2023 Apr 15. doi: 10.1002/cncr.34802.
    PubMed     Abstract available


    February 2023
  4. OH DY, Algazi A, Capdevila J, Longo F, et al
    Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
    Cancer. 2023 Feb 7. doi: 10.1002/cncr.34657.
    PubMed     Abstract available


    January 2023

  5. Erratum to "Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial".
    Cancer. 2023 Jan 13. doi: 10.1002/cncr.34638.
    PubMed    


    October 2022
  6. BROSE MS, Robinson BG, Sherman SI, Jarzab B, et al
    Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34493.
    PubMed     Abstract available


    April 2022
  7. KIYOTA N, Tahara M, Robinson B, Schlumberger M, et al
    Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
    Cancer. 2022 Apr 5. doi: 10.1002/cncr.34181.
    PubMed     Abstract available


    October 2021
  8. CHEMAITILLY W, Li Z, Brinkman TM, Delaney A, et al
    Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences.
    Cancer. 2021 Oct 13. doi: 10.1002/cncr.33969.
    PubMed     Abstract available


    July 2021
  9. ROMESSER PB, Sherman EJ, Whiting K, Ho ML, et al
    Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33804.
    PubMed     Abstract available


  10. XIAO Q, Kitahara CM
    Reply to associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33685.
    PubMed    


  11. XIAO P, Li L, Ding S, Xie J, et al
    Associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33686.
    PubMed    


    February 2021
  12. ZHANG D, Jones RR, James P, Kitahara CM, et al
    Associations between artificial light at night and risk for thyroid cancer: A large US cohort study.
    Cancer. 2021 Feb 8. doi: 10.1002/cncr.33392.
    PubMed     Abstract available


  13. YIP L, Gooding WE, Nikitski A, Wald AI, et al
    Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study.
    Cancer. 2021 Feb 4. doi: 10.1002/cncr.33421.
    PubMed     Abstract available


    January 2021
  14. ALHUMAIDI H, Manochakian R, Cochuyt J, Chindris A, et al
    Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33408.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diseases of the Thyroid is free of charge.